The endocannabinoid system (ECS) is a recently emerging complex regulator of multiple physiological processes. It comprises several endogenous ligands (e.g. *N*-arachidonoylethanolamine, a.k.a. anandamide \[AEA\], 2-arachidonoylglycerol \[2-AG\], palmitoylethanolamide \[PEA\], etc.), a number of endocannabinoid (eCB)-responsive receptors (e.g. CB~1~ and CB~2~, etc.), as well as enzymes and transporters involved in the synthesis and degradation of the eCBs (extensively reviewed in [@bb0025], [@bb0020]).

Among many other tissues and organs, various members of the ECS were shown to be expressed in the skin as well. Indeed, AEA, 2-AG, CB~1~ and CB~2~ together with the major eCB-metabolizing enzymes (e.g. fatty acid amide hydrolase \[FAAH\], which cleaves AEA to ethanolamine and pro-inflammatory arachidonic acid) were found in various cutaneous cell types. Importantly, the eCB-tone and cannabinoid signaling in general appear to play a key role in regulating several fundamental aspects of cutaneous homeostasis, including proliferation and differentiation of epidermal keratinocytes, hair growth, sebaceous lipid production, melanogenesis, fibroblast activity, etc. (reviewed in [@bb0005], [@bb0025]). Moreover, appropriate eCB-signaling through CB~1~ and CB~2~ receptors was found to be crucially important in keeping cutaneous inflammatory processes under control ([@bb0015]). Indeed, by using CB~1~ and CB~2~ double KO (DKO) as well as wild-type (WT) mice, Karsak et al. demonstrated that DKO animals, lacking appropriate epidermal cannabinoid signaling, displayed exacerbated allergic skin inflammation, most probably because of the elevated MCP-2/CCL8 chemokine production of the epidermal keratinocytes. On the other hand, FAAH^−/−^ mice (having higher eCB tone due to the impaired AEA degradation) exhibited less severe symptoms, and inflammation was also alleviated by cannabinoid receptor agonists in WT animals ([@bb0015]). Moreover, AEA was recently shown to suppress production and release of key Th1- and Th17-polarizing cytokines (IL-12 and IL-23) via CB~1~-mediated inhibition of mammalian target of rapamycin (mTOR) in human keratinocytes ([@bb0010]). Collectively, these findings (together with many other recently published data) implied keratinocytes to be "non-classical" immune competent cells, playing a central role in initiation and regulation of cutaneous immune processes, and the "*c(ut)an*nabinoid" system is now proven to be one of their master regulators.

On the footsteps of Karsak et al., we further investigated the immunological role of the eCB-signaling using human epidermal keratinocytes. We found that protein (but, interestingly, not mRNA) expression and activity of the aforementioned eCB-degrading enzyme FAAH was positively regulated by Toll-like receptor (TLR) 2 activation ([@bb0035]). This quite fascinating result clearly demonstrated how deeply the ECS is involved in the regulation of one of the most fundamental immune processes, i.e. the TLR-activation-induced pro-inflammatory signaling. Indeed, administration of selective FAAH-inhibitors (and thereby restoration of the homeostatic, anti-inflammatory eCB signaling leading to the activation of CB~1~ and CB~2~ receptors) was able to almost completely abrogate the TLR2-mediated pro-inflammatory response ([@bb0035]). Moreover, topically applied FAAH-inhibitors alleviated atopic dermatitis (AD)-like symptoms of Nc/Tnd mice (a.k.a. NC/Nga; a mouse strain developing AD-like skin condition upon meeting certain dust mite antigens; [@bb0045]) too ([@bb0035]). Based on these data, FAAH appears to be an important "decision maker" in the initiation and maintenance of cutaneous inflammation; thus, increase/restoration of the homeostatic cutaneous eCB tone by topically applied FAAH-inhibitors possesses great potential in alleviating skin inflammation ([Fig. 1](#f0005){ref-type="fig"}A).Fig. 1Classical and "non-classical" cannabinoid pathways in cutaneous inflammation.A) TLR2-activation increases FAAH expression and activity in human epidermal keratinocytes, leading to the loss of homeostatic, anti-inflammatory eCB signaling and therefore results in elevated pro-inflammatory cytokine expression and release. Thus, FAAH-inhibitors can selectively target the very first step of the cutaneous inflammatory processes by restoring the epidermal anti-inflammatory eCB-tone, and thereby normalizing the cytokine expression and release of the keratinocytes ([@bb0035]). B) Schematic overview of the mechanism of CBD\'s complex anti-acne effects ([@bb0030]).A~2A~: adenosine receptor 2A; AA: arachidonic acid; AEA: anandamide; FAAH: fatty acid amide hydrolase; ERK1/2: extracellular signal-regulated kinase 1 and 2; MAPK: mitogen activated protein kinase; NF-κB: nuclear factor kappa-light-chain enhancer of activated B cells; NRIP1: nuclear receptor interacting protein 1; TLR: Toll-like receptor; TRIB3: tribbles homolog 3; TRPV4: transient receptor potential vanilloid 4.Fig. 1

Another recently emerging, fascinating possibility to manage cutaneous inflammation through the cannabinoid signaling is the administration of phytocannabinoids (pCB). *Cannabis sativa* contains over 100 different pCBs, the vast majority of which have no psychotropic activity, and usually possess a "favorable" side-effect profile, which makes these substances particularly interesting drug candidates in treating several inflammation-accompanied diseases ([@bb0025], [@bb0020]). With respect to the skin, we have recently shown that one of the best studied pCBs, (−)-cannabidiol (CBD), may have great potential in managing acne, an inflammation-accompanied, extremely prevalent cutaneous disease. Briefly, we found that without decreasing either the viability or basal sebaceous lipid production, CBD normalized acne-mimicking, seborrheic lipid synthesis, decreased proliferation of sebocytes, and exerted strong anti-inflammatory actions via "non-classical" cannabinoid pathways ([Fig. 1](#f0005){ref-type="fig"}B). Indeed, sebostatic (lipid lowering and anti-proliferative) actions were found to be coupled to the activation of transient receptor potential vanilloid 4 (TRPV4) ion channels followed by the subsequent inhibition of the ERK1/2 MAPK pathway and down-regulation of nuclear receptor interacting protein 1 (NRIP1, a.k.a. RIP140). On the other hand, anti-inflammatory effects were realized by the (most probably indirect) activation of A~2A~ adenosine receptors followed by up-regulation of tribbles homolog 3 (TRIB3) and inhibition of the pro-inflammatory p65 NF-κB pathway ([@bb0030]). Moreover, although they exhibited important functional heterogeneity in influencing sebaceous lipogenesis, several other pCBs (namely (−)-cannabichromene \[CBC\], (−)-cannabidivarin \[CBDV\], (−)-cannabigerol \[CBG\], (−)-cannabigerovarin \[CBGV\] and (−)-Δ^9^-tetrahydrocannabidivarin \[THCV\]) were proven to exert potent anti-inflammatory actions in human sebocytes ([@bb0040]).

Collectively, in light of the above results, both increase/restoration of the homeostatic cutaneous eCB-tone by FAAH-inhibitors and topical administration of non-psychotropic pCBs hold out the promise to exert remarkable anti-inflammatory actions, making them very exciting drug candidates, deserving full clinical exploration as potent, yet safe ([@bb0025], [@bb0020]) novel class of anti-inflammatory agents.
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